WO2000069901A3 - Proteins with insulin-like activity useful in the treatment of diabetes - Google Patents

Proteins with insulin-like activity useful in the treatment of diabetes Download PDF

Info

Publication number
WO2000069901A3
WO2000069901A3 PCT/US2000/013764 US0013764W WO0069901A3 WO 2000069901 A3 WO2000069901 A3 WO 2000069901A3 US 0013764 W US0013764 W US 0013764W WO 0069901 A3 WO0069901 A3 WO 0069901A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
proteins
insulin
treatment
activity useful
Prior art date
Application number
PCT/US2000/013764
Other languages
French (fr)
Other versions
WO2000069901A2 (en
Inventor
Bassil I Dahiyat
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to CA002372393A priority Critical patent/CA2372393A1/en
Priority to AU51444/00A priority patent/AU5144400A/en
Priority to JP2000618317A priority patent/JP2003518917A/en
Publication of WO2000069901A2 publication Critical patent/WO2000069901A2/en
Publication of WO2000069901A3 publication Critical patent/WO2000069901A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to novel insulin activity (IA) proteins and nucleic acids. The invention further relates to the use of the IA proteins in the treatment of insulin related disorders such as type 1 diabetes and type 2 diabetes.
PCT/US2000/013764 1999-05-19 2000-05-19 Proteins with insulin-like activity useful in the treatment of diabetes WO2000069901A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002372393A CA2372393A1 (en) 1999-05-19 2000-05-19 Novel proteins with insulin-like activity useful in the treatment of diabetes
AU51444/00A AU5144400A (en) 1999-05-19 2000-05-19 Novel proteins with insulin-like activity useful in the treatment of diabetes
JP2000618317A JP2003518917A (en) 1999-05-19 2000-05-19 Novel protein with insulin-like activity useful for the treatment of diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13493099P 1999-05-19 1999-05-19
US60/134,930 1999-05-19

Publications (2)

Publication Number Publication Date
WO2000069901A2 WO2000069901A2 (en) 2000-11-23
WO2000069901A3 true WO2000069901A3 (en) 2002-09-12

Family

ID=22465651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013764 WO2000069901A2 (en) 1999-05-19 2000-05-19 Proteins with insulin-like activity useful in the treatment of diabetes

Country Status (4)

Country Link
JP (1) JP2003518917A (en)
AU (1) AU5144400A (en)
CA (1) CA2372393A1 (en)
WO (1) WO2000069901A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042550D1 (en) 1999-01-06 2009-08-27 Genentech Inc MUTED VARIANTS OF THE INSULIN-SIMILAR GROWTH FACTOR I (IGF-I)
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ES2301547T3 (en) 2000-05-16 2008-07-01 Genentech, Inc. TREATMENT OF CARTILAGO DISORDERS.
WO2005005477A2 (en) * 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US20110294729A1 (en) * 2008-12-09 2011-12-01 Novo Nordisk A/S Novel Insulin Analogues
JP2014509603A (en) * 2011-03-15 2014-04-21 ノヴォ ノルディスク アー／エス Human insulin analogues and human insulin derivatives containing cysteine substitutions
JP6499184B2 (en) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス Novel derivatives of insulin analogues
BR112019011761A2 (en) 2016-12-16 2019-11-05 Novo Nordisk As insulin-containing pharmaceutical compositions
WO2019034726A1 (en) * 2017-08-17 2019-02-21 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
CN112843082B (en) * 2021-02-02 2022-07-05 四川大学 Application of DNA tetrahedron in preparation of medicine for treating diabetes
CN112843081B (en) * 2021-02-02 2022-07-05 四川大学 DNA tetrahedron-resveratrol compound and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003174A1 (en) * 1991-08-08 1993-02-18 Scios Inc. Tissue-selective insulin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003174A1 (en) * 1991-08-08 1993-02-18 Scios Inc. Tissue-selective insulin analogs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. MOL. BIOL. INT. (1997), 43(4), 705-711 *
BIOCHIM. BIOPHYS. ACTA (1998), 1429(1), 69-73 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BRANGE, J. ET AL: "Design of novel insulins with changed self-association and ligand binding properties", XP002167132, retrieved from STN Database accession no. 115:85565 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, HUI ET AL: "Hydrophilic Thr can replace the hydrophobic and absolutely conservative A3Val in insulin", XP002167130, retrieved from STN Database accession no. 130:192138 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SASAKI, ATSUKO ET AL: "Tertiary structure analysis of receptor binding ability of mutant insulins", XP002167133, retrieved from STN Database accession no. 115:985 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHI, MIN ET AL: "Studies on growth-promoting action of insulin: mitogenic activity of insulin and its analogs in mouse mammary tumor cells", XP002167131, retrieved from STN Database accession no. 128:149680 *
GBF MONOGR. (1989), 12(ADV. PROTEIN DES.), 139-44 *
JIKEIKAI MED. J. (1990), 37(3), 343-53 *
NAKAGAWA, SATOE H. ET AL: "Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions", BIOCHEMISTRY (1992), 31(12), 3204-14, XP002167129 *

Also Published As

Publication number Publication date
CA2372393A1 (en) 2000-11-23
AU5144400A (en) 2000-12-05
JP2003518917A (en) 2003-06-17
WO2000069901A2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
WO2000068387A3 (en) Nucleic acids and proteins with interferon-beta activity
WO2000069901A3 (en) Proteins with insulin-like activity useful in the treatment of diabetes
WO2000074666A3 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
EP0926159A3 (en) Glucagon-like peptide-1 crystals
AU3791799A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO2000044928A3 (en) Materials and methods for the purification of polyelectrolytes
EP2292771A3 (en) Sense mRNA therapy
AU1516301A (en) Use of a milk protein hydrolysate in the treatment of diabetes
EP1724284A3 (en) GLP-1 fusion proteins
IE891798L (en) Novel ó-glucosidase inhibitors
AU3997300A (en) Gene sequence variations with utility in determining the treatment of disease
AU2003234529A1 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
EP2298355A3 (en) Albumin fusion proteins
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
CA2281895A1 (en) Ikb kinases
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
AU2670495A (en) Ifn-beta liquid formulations
WO2003092612A3 (en) VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
WO1997009420A3 (en) Dna sequences coding for a human metalloproteinase and variants thereof
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
AU2205099A (en) Chimeric proteins for the treatment of diabetes
EP2270230A3 (en) Antisense modulation of insulin-like growth factor binding protein 5 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2372393

Country of ref document: CA

Ref country code: CA

Ref document number: 2372393

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618317

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 51444/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000936077

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000936077

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG